Lung Cancer Panel Discussion: Should Biomarker Testing Be Performed on Patients With SCC? Are There Ongoing Trials for Rare NSCLC Mutations? What TT Options Exist for Patients With Driver Mutations?

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2024 Ovarian Cancer Program
Basic Science
Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast

Playback speed

September 11, 2023

Feat. A. Whiteley

Targeted Therapies in Lung Cancer 2023

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

I. Preeshagul

Login

Login

Join VuMedi

GRACE

Lung Cancer Panel Discussion: Should Biomarker Testing Be Performed on Patients With SCC? Are There Ongoing Trials for Rare NSCLC Mutations? What TT Options Exist for Patients With Driver Mutations?

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Optimizing the Management of Patients with Polycythemia Vera (PV)

Lung Cancer Panel Discussion: Resistance on Targeted Therapy - Quest…

Lung Cancer Panel Discussion: Why Some Patients Remain on TKIs Witho…

Lung Cancer Panel Discussion: What Do We Know About Prevention and C…

NSCLC Panel Discussion: Should a Patient With High PD-L1 Wait for Ge…

Targeted Therapies in Lung Cancer 2023: Does Radiation Increase Toxi…

Targeted Therapies in Lung Cancer 2023: Is Biomarker Testing Common …

Lung Cancer Panel Discussion: Should Biomarker Testing Be Performed …

Targeted Therapies in Lung Cancer 2023: Novel Treatment Approaches i…

Targeted Therapies in Lung Cancer 2023: RET and Other Rare Fusions i…

Targeted Therapies in Lung Cancer 2023: Biomarker Testing for NSCLC …

Targeted Therapies in Lung Cancer 2023: Non-Metastatic NSCLC and Tar…

Targeted Therapies in Lung Cancer 2023: Helping TKIs Maximize Their …

Targeted Therapies in Lung Cancer 2023: EGFR Targeted Therapies in N…

Targeted Therapies in Lung Cancer 2023: Translating Cancer Discovery…

Targeted Therapies in Lung Cancer 2023: Symptom Management and Palli…

Targeted Therapies in Lung Cancer 2023: The Future of Local Therapy

Targeted Therapies in Lung Cancer 2023: Barriers to Biomarker Testin…

Targeted Therapies in Lung Cancer 2023: The ADAURA Trial for NSCLC -…

Targeted Therapies in Lung Cancer 2023: Key Points From the ADAURA T…

Targeted Therapies in Lung Cancer 2023: Neoadjuvant Treatment for Pa…

Targeted Therapies in Lung Cancer 2023: Biomarker Driven Therapy for…

Targeted Therapies in Lung Cancer 2023: Current Recommendations and …

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Targeted Therapies in Lung Cancer 2023: The Importance of Biomarker …

Targeted Therapies in Lung Cancer 2023: Barriers to Biomarker Testin…